Literature DB >> 33664322

Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.

Marketa Koleckova1, Jiri Ehrmann1, Jan Bouchal2,3, Maria Janikova1, Aneta Brisudova1, Josef Srovnal4, Katerina Staffova4, Marek Svoboda5, Ondrej Slaby5, Lenka Radova5, Katherine Vomackova6, Bohuslav Melichar7, Lucia Veverkova8, Zdenek Kolar9,10.   

Abstract

Triple negative breast cancers (TNBC) are a morphologically and genetically heterogeneous group of breast cancers with uncertain prediction of biological behavior and response to therapy. Epithelial to mesenchymal transition (EMT) is a dynamic process characterized by loss of typical epithelial phenotype and acquisition of mesenchymal characteristics. Aberrant activation of EMT can aggravate the prognosis of patients with cancer, however, the mechanisms of EMT and role of microRNAs (miRNAs) in EMT activation is still unclear. The aim of our study was to analyze miRNA expression within areas of TNBCs with cellular morphology that may be related to the EMT process and discuss possible associations. Out of all 3953 re-examined breast cancers, 460 breast cancers were diagnosed as TNBC (11.64%). With regard to complete tumor morphology preservation, the tissue samples obtained from core-cut biopsies and influenced by previous neoadjuvant therapy were excluded. We assembled a set of selected 25 cases to determine miRNA expression levels in relation to present focal spindle cell and apocrine cell morphology within individual TNBCs. We used descriptive (histological typing and morphology), morphometric, molecular (microdissection of tumor and non-tumor morphologies, RNA isolation and purification, microchip analysis) and bioinformatic analysis (including pathway analysis). The results were verified by quantitative real-time PCR (RT-qPCR) on an extended set of 70 TNBCs. The majority of TNBCs were represented by high-grade invasive carcinomas of no special type (NST) with medullary features characterized by well-circumscribed tumors with central necrosis or fibrosis and frequent tendency to spindle-cell and/or apocrine cell transformation. Apocrine and spindle cell transformation showed a specific miRNA expression profile in comparison to other tumor parts, in situ carcinoma or non-tumor structures, particularly down-regulated expression of hsa-miRNA-143-3p and hsa-miRNA-205-5p and up-regulated expression of hsa-miR-22-3p, hsa-miRNA-185-5p, and hsa-miR-4443. Apocrine cell tumor morphology further revealed decreased expression of hsa-miR-145-5p and increased expression of additional 14 miRNAs (e.g. hsa-miR-182-5p, hsa-miR-3135b and hsa-miR-4417). Pathway analysis for target genes of these miRNAs revealed several shared biological processes (i.e. Wnt signaling, ErbB signaling, MAPK signaling, endocytosis and axon guidance), which may in part contribute to the EMT and tumor progression. We provide the first miRNA expression profiling of specific tissue morphologies in TNBC. Our results demonstrate a specific miRNA expression profile of apocrine and spindle cell morphology which can exhibit a certain similarity with the EMT process and may also be relevant for prognosis and therapy resistance of TNBC.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33664322      PMCID: PMC7933252          DOI: 10.1038/s41598-021-84350-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  83 in total

Review 1.  The epigenetics of epithelial-mesenchymal plasticity in cancer.

Authors:  Wai Leong Tam; Robert A Weinberg
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

2.  MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.

Authors:  Chen Khuan Wong; Christopher Gromisch; Sait Ozturk; Panagiotis Papageorgis; Hamid Mostafavi Abdolmaleky; Björn M Reinhard; Arunthathi Thiagalingam; Sam Thiagalingam
Journal:  Cancer Biol Ther       Date:  2019-03-28       Impact factor: 4.742

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin.

Authors:  N Zhang; X Wang; Q Huo; M Sun; C Cai; Z Liu; G Hu; Q Yang
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

Review 5.  Identification of dysregulated microRNAs in triple-negative breast cancer (review).

Authors:  Fang Yang; Wenwen Zhang; Yan Shen; Xiaoxiang Guan
Journal:  Int J Oncol       Date:  2015-01-08       Impact factor: 5.650

6.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

7.  MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.

Authors:  Zhishuang Li; Qingyong Meng; Aifeng Pan; Xiaojuan Wu; Jingjing Cui; Yan Wang; Li Li
Journal:  Oncotarget       Date:  2017-03-21

8.  Hsa-miRNA-143-3p Reverses Multidrug Resistance of Triple-Negative Breast Cancer by Inhibiting the Expression of Its Target Protein Cytokine-Induced Apoptosis Inhibitor 1 In Vivo.

Authors:  Yu Wei Deng; Wen Jing Hao; Yi Wen Li; Yi Xin Li; Bo Chen Zhao; Dan Lu
Journal:  J Breast Cancer       Date:  2018-09-12       Impact factor: 3.588

9.  miR-29a contributes to breast cancer cells epithelial-mesenchymal transition, migration, and invasion via down-regulating histone H4K20 trimethylation through directly targeting SUV420H2.

Authors:  You Wu; Wanyue Shi; Tingting Tang; Yidong Wang; Xin Yin; Yanlin Chen; Yanfeng Zhang; Yun Xing; Yumeng Shen; Tiansong Xia; Changying Guo; Yi Pan; Liang Jin
Journal:  Cell Death Dis       Date:  2019-02-21       Impact factor: 8.469

10.  Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.

Authors:  Qian Wang; Yu Cheng; Yan Wang; Yibo Fan; Ce Li; Ye Zhang; Yiding Wang; Qian Dong; Yanju Ma; Yue-E Teng; Xiujuan Qu; Yunpeng Liu
Journal:  BMC Cancer       Date:  2017-07-19       Impact factor: 4.430

View more
  5 in total

1.  Marine-Derived Stichloroside C2 Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis through the Mitogen-Activated Protein Kinase Signalling Pathway in Triple-Negative Breast Cancer Cells.

Authors:  Chuang Cui; Chen-Huan Ding; Fang-Fang Liu; Jing-Rong Lu; Shi-Yun Zheng; Hou-Wen Lin; Wei-Kang Zhu; Fan Yang; He Li
Journal:  J Oncol       Date:  2022-05-14       Impact factor: 4.501

2.  microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition.

Authors:  Bingfeng Luo; Yuan Yuan; Yifei Zhu; Songwu Liang; Runan Dong; Jian Hou; Ping Li; Yaping Xing; Zhenquan Lu; Richard Lo; Guan-Ming Kuang
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

3.  miRSCAPE - inferring miRNA expression from scRNA-seq data.

Authors:  Gulden Olgun; Vishaka Gopalan; Sridhar Hannenhalli
Journal:  iScience       Date:  2022-08-17

Review 4.  The Roles of DNA Demethylases in Triple-Negative Breast Cancer.

Authors:  Shoghag Panjarian; Jean-Pierre J Issa
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-29

5.  Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion.

Authors:  Lavinia Raimondi; Alessia Gallo; Nicola Cuscino; Angela De Luca; Viviana Costa; Valeria Carina; Daniele Bellavia; Matteo Bulati; Riccardo Alessandro; Milena Fini; Pier Giulio Conaldi; Gianluca Giavaresi
Journal:  Int J Mol Sci       Date:  2022-01-09       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.